OAR 847-065-0015

The following definitions apply to OAR chapter 847, division 065, except as otherwise stated in the definition:


“Assessment or evaluation” means the process an independent third-party evaluator uses to diagnose the licensee and to recommend treatment options for the licensee.


“Board” means the Oregon Medical Board.


“Business day” means Monday through Friday, except legal holidays as defined in ORS 187.010 (Legal holidays) (or ORS 187.020 (Additional legal holidays)).


“Contractor” means the entity that has contracted with the Division to conduct the HPSP.


“Diagnosis” means the principal mental health or substance use diagnosis listed in the current Diagnostic Statistical Manual (DSM). The diagnosis is determined through the assessment and any examinations, tests or consultations suggested by the assessment.


“Division” means the Department of Human Services, Addictions and Mental Health Division.


“DSM” means the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association.


“Federal regulations” means:


As used in ORS 676.185 (Definitions for ORS 676.185 to 676.200)(5)(d), a “positive toxicology test result as determined by federal regulations pertaining to drug testing” means a test result that meets or exceeds the cutoff concentrations shown in 49 CFR § 40.87 (2009); and


As used in ORS 676.190 (Establishment of program)(5)(g), requiring a “licensee to submit to random drug or alcohol testing in accordance with federal regulations” means licensees are selected for random testing by a scientifically valid method, such as a random number table or a computer-based random number generator that is matched with licensees’ unique identification numbers or other comparable identifying numbers. Under the selection process used, each covered licensee must have an equal chance of being tested each time selections are made, as described in 40 CFR § 199.105(c)(5) (2009). Random drug tests must be unannounced and the dates for administering random tests must be spread reasonably throughout the calendar year, as described in 40 CFR § 199.105(c)(7) (2009).


“Fitness to practice evaluation” means the process a qualified, independent third-party evaluator uses to determine if the licensee can safely perform the essential functions of the licensee’s health practice.


“Final enrollment” means a licensee has provided all documentation required by OAR 847-065-0035 (Procedure for Self-Referred Licensees) and has met all eligibility requirements to participate in the HPSP.


“Independent third-party evaluator” means an individual or center who is approved by the Board to evaluate, diagnose, and offer treatment options for substance use disorders and/or mental disorders.


“Licensee” means a licensed physician, podiatric physician, physician assistant or acupuncturist who is licensed or certified by the Board.


“Mental disorder” means a clinically significant syndrome identified in the current DSM that is associated with disability or with significantly increased risk of disability.


“Monitoring agreement” means an individualized agreement between a licensee and the contractor that meets the requirements for a diversion agreement set by ORS 676.190 (Establishment of program).


“Positive toxicology test result” means a test result that meets or exceeds the cutoff concentrations shown in 49 CFR 40.87 (2009), a test result that shows other drugs or alcohol, or a test result that fails to show the appropriate presence of a currently prescribed drug that is part of a treatment program related to a condition being monitored by HPSP.


“Provisional enrollment” means temporary enrollment, pending verification that a licensee meets all program eligibility criteria.


“Self-referred licensee” means a licensee who seeks to participate in the program without a referral from the Board.


“Substance abuse” means a disorder related to the taking of a drug of abuse (including alcohol); to the side effects of a medication; and to a toxin exposure, including: substance use disorders (substance dependence and substance abuse) and substance-induced disorders (including but not limited to substance intoxication, withdrawal, delirium, and dementia, as well as substance induced psychotic disorders and mood disorders), as defined in DSM criteria.


“Substantial non-compliance” means that a licensee is in violation of the terms of his or her monitoring agreement in a way that gives rise to concerns about the licensee’s ability or willingness to participate in the HPSP. Substantial non-compliance and non-compliance include, but are not limited to, the factors listed in ORS 676.185 (Definitions for ORS 676.185 to 676.200)(5). Conduct that occurred before a licensee entered into a monitoring agreement does not violate the terms of that monitoring agreement.


“Toxicology testing” means urine testing or alternative chemical monitoring including blood, saliva, breath or hair as conducted by a laboratory certified, accredited or licensed and approved for toxicology testing.


“Treatment” means the planned, specific, individualized health and behavioral-health procedures, activities, services and supports that a treatment provider uses to remediate symptoms of a substance use disorder and/or mental disorder.
Last Updated

Jun. 8, 2021

Rule 847-065-0015’s source at or​.us